Abstract
Paragangliomas are rare vascular tumors of neuroectodermal tissue arising from neural crest cells. They can be found at various locations of the paraganglion system throughout the body. Tumors originating from chromaffin cells of the adrenal medulla are referred to as pheochromocytomas. Most paragangliomas are benign, but morbidity can result from either growth and compression of nearby structures or physiologic derangements secondary to abnormal secretion of catecholamines. The vast majority of head and neck paragangliomas are nonsecretory [1, 2].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Williams MD, Rich TA. Paragangliomas arising in the head and neck. A Morphologic Review and Genetic Update. Surg Pathol Clin. 2014;7(4):543–57.
Moore MG, Netterville JL, Mendenhall WM, Isaacson B, Nussenbaum B. Head and neck Paragangliomas: an update on evaluation and management. Otolaryngol Head Neck Surg. 2016;154(4):597–605.
Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287(5454):848–51.
Pawlu C, Bausch B, Neumann HP. Mutations of the SDHB and SDHD genes. Familial Cancer. 2005;4(1):49–54.
Gimenez-Roqueplo AP, Dahia PL, Robledo M. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res. 2012;44(5):328–33.
Dahia PL. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer. 2014;14(2):108–19.
Neumann HP, Erlic Z, Boedeker CC, et al. Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res. 2009;69(8):3650–6.
Arias-Stella J, Valcarcel J. Chief cell hyperplasia in the human carotid body at high altitudes; physiologic and pathologic significance. Hum Pathol. 1976;7(4):361–73.
Cornog JL, Wilkinson JH, Arvan DA, Freed RM, Sellers AM, Barker C. Extra-adrenal pheochromocytoma. Some electron microscopic and biochemical studies. Am J Med. 1970;48(5):654–60.
Arias-Stella J, Valcarcel J. The human carotid body at high altitudes. Pathol Microbiol (Basel). 1973;39(3):292–7.
Watanabe H, Burnstock G, Jarrott B, Louis WJ. Mitochondrial abnormalities in human pheochromocytoma. Cell Tissue Res. 1976;172(2):281–8.
Baysal BE, Willett-Brozick JE, Lawrence EC, et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet. 2002;39(3):178–83.
Burnichon N, Briere JJ, Libe R, et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet. 2010;19(15):3011–20.
Hao HX, Khalimonchuk O, Schraders M, et al. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science. 2009;325(5944):1139–42.
Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet. 2000;26(3):268–70.
Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet. 2001;69(1):49–54.
Benn DE, Robinson BG, Clifton-Bligh RJ. 15 YEARS OF PARAGANGLIOMA: clinical manifestations of paraganglioma syndromes types 1-5. Endocr Relat Cancer. 2015;22(4):T91–103.
Offergeld C, Brase C, Yaremchuk S, et al. Head and neck paragangliomas: clinical and molecular genetic classification. Clinics (Sao Paulo). 2012;67(Suppl 1):19–28.
Jafri M, Whitworth J, Rattenberry E, et al. Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma. Clin Endocrinol. 2013;78(6):898–906.
Astuti D, Douglas F, Lennard TW, et al. Germline SDHD mutation in familial phaeochromocytoma. Lancet. 2001;357(9263):1181–2.
Ricketts CJ, Forman JR, Rattenberry E, et al. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat. 2010;31(1):41–51.
Xekouki P, Szarek E, Bullova P, et al. Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice. J Clin Endocrinol Metab. 2015;100(5):E710–9.
Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004;292(8):943–51.
Benn DE, Gimenez-Roqueplo AP, Reilly JR, et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab. 2006;91(3):827–36.
Taschner PE, Jansen JC, Baysal BE, et al. Nearly all hereditary paragangliomas in the Netherlands are caused by two founder mutations in the SDHD gene. Genes Chromosomes Cancer. 2001;31(3):274–81.
Neumann HP, Erlic Z. Maternal transmission of symptomatic disease with SDHD mutation: fact or fiction? J Clin Endocrinol Metab. 2008;93(5):1573–5.
Yeap PM, Tobias ES, Mavraki E, et al. Molecular analysis of pheochromocytoma after maternal transmission of SDHD mutation elucidates mechanism of parent-of-origin effect. J Clin Endocrinol Metab. 2011;96(12):E2009–13.
King KS, Pacak K. Familial pheochromocytomas and paragangliomas. Mol Cell Endocrinol. 2014;386(1-2):92–100.
Bayley JP, Kunst HP, Cascon A, et al. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol. 2010;11(4):366–72.
Kunst HP, Rutten MH, de Monnink JP, et al. SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma. Clin Cancer Res. 2011;17(2):247–54.
Schiavi F, Boedeker CC, Bausch B, et al. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA. 2005;294(16):2057–63.
Mannelli M, Ercolino T, Giache V, Simi L, Cirami C, Parenti G. Genetic screening for pheochromocytoma: should SDHC gene analysis be included? J Med Genet. 2007;44(9):586–7.
Burnichon N, Rohmer V, Amar L, et al. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab. 2009;94(8):2817–27.
Buffet A, Venisse A, Nau V, et al. A decade (2001–2010) of genetic testing for pheochromocytoma and paraganglioma. Horm Metab Res. 2012;44(5):359–66.
Srirangalingam U, LeCain M, Tufton N, Akker SA, Drake WM, Metcalfe K. Four generations of SDHB-related disease: complexities in management. Familial Cancer. 2016;16(2):279–82.
Timmers HJ, Kozupa A, Eisenhofer G, et al. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2007;92(3):779–86.
Brouwers FM, Eisenhofer G, Tao JJ, et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab. 2006;91(11):4505–9.
Schiavi F, Milne RL, Anda E, et al. Are we overestimating the penetrance of mutations in SDHB? Hum Mutat. 2010;31(6):761–2.
Korpershoek E, Favier J, Gaal J, et al. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab. 2011;96(9):E1472–6.
Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–42.
Erlic Z, Rybicki L, Peczkowska M, et al. Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Clin Cancer Res. 2009;15(20):6378–85.
Martin TP, Irving RM, Maher ER. The genetics of paragangliomas: a review. Clin Otolaryngol. 2007;32(1):7–11.
Raygada M, Pasini B, Stratakis CA. Hereditary paragangliomas. Adv Otorhinolaryngol. 2011;70:99–106.
Gill AJ, Benn DE, Chou A, et al. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Hum Pathol. 2010;41(6):805–14.
Castelblanco E, Santacana M, Valls J, et al. Usefulness of negative and weak-diffuse pattern of SDHB immunostaining in assessment of SDH mutations in paragangliomas and pheochromocytomas. Endocr Pathol. 2013;24(4):199–205.
Carlson ML, Sweeney AD, Wanna GB, Netterville JL, Haynes DS. Natural history of glomus jugulare: a review of 16 tumors managed with primary observation. Otolaryngol Head Neck Surg. 2015;152(1):98–105.
Wanna GB, Sweeney AD, Haynes DS, Carlson ML. Contemporary management of jugular paragangliomas. Otolaryngol Clin N Am. 2015;48(2):331–41.
Gilbo P, Morris CG, Amdur RJ, et al. Radiotherapy for benign head and neck paragangliomas: a 45-year experience. Cancer. 2014;120(23):3738–43.
Myssiorek D, Ferlito A, Silver CE, et al. Screening for familial paragangliomas. Oral Oncol. 2008;44(6):532–7.
Thirlwall AS, Bailey CM, Ramsay AD, Wyatt M. Laryngeal paraganglioma in a five-year-old child—the youngest case ever recorded. J Laryngol Otol. 1999;113(1):62–4.
Kwekkeboom DJ, van Urk H, Pauw BK, et al. Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med. 1993;34(6):873–8.
Myssiorek D, Palestro CJ. 111Indium pentetreotide scan detection of familial paragangliomas. Laryngoscope. 1998;108(2):228–31.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
O’Connell, B.P., Wanna, G.B. (2018). Familial Head and Neck Paraganglioma and Genetic Testing. In: Wanna, G., Carlson, M., Netterville, J. (eds) Contemporary Management of Jugular Paraganglioma. Springer, Cham. https://doi.org/10.1007/978-3-319-60955-3_15
Download citation
DOI: https://doi.org/10.1007/978-3-319-60955-3_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-60954-6
Online ISBN: 978-3-319-60955-3
eBook Packages: MedicineMedicine (R0)